Topiramate Patent Expiration

Topiramate is Used for preventing migraines in patients 12 years and older. It was first introduced by Janssen Pharmaceuticals Inc in its drug Topamax on Dec 24, 1996. Other drugs containing Topiramate are Trokendi Xr, Eprontia, Topamax Sprinkle, Qudexy Xr. 42 different companies have introduced drugs containing Topiramate.


Topiramate Patents

Given below is the list of patents protecting Topiramate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Eprontia US11433046 Compositions and methods for treating epilepsy, seizures and other conditions Aug 21, 2040 Azurity
Eprontia US11633374 Compositions and methods for treating epilepsy, seizures and other conditions Aug 21, 2040 Azurity
Eprontia US11826343 Compositions and methods for treating epilepsy, seizures and other conditions Aug 21, 2040 Azurity
Eprontia US11911362 Compositions and methods for treating epilepsy, seizures and other conditions Aug 21, 2040 Azurity
Eprontia US12290503 Compositions and methods for treating epilepsy, seizures and other conditions Aug 21, 2040 Azurity
Qudexy Xr US10363224 Extended-release topiramate capsules Mar 19, 2033 Upsher Smith Labs
Qudexy Xr US8652527 Extended-release topiramate capsules Mar 19, 2033 Upsher Smith Labs
Qudexy Xr US8889190 Extended-release topiramate capsules Mar 19, 2033 Upsher Smith Labs
Qudexy Xr US9101545 Extended-release topiramate capsules Mar 19, 2033 Upsher Smith Labs
Qudexy Xr US9555005 Extended-release topiramate capsules Mar 19, 2033 Upsher Smith Labs
Trokendi Xr US8298576 Sustained-release formulations of topiramate Apr 04, 2028 Supernus Pharms
Trokendi Xr US10314790 Sustained-release formulations of topiramate Nov 16, 2027 Supernus Pharms
Trokendi Xr US8298580 Sustained-release formulations of topiramate Nov 16, 2027 Supernus Pharms
Trokendi Xr US8663683 Sustained-release formulations of topiramate Nov 16, 2027 Supernus Pharms
Trokendi Xr US8877248 Sustained-release formulations of topiramate Nov 16, 2027 Supernus Pharms
Trokendi Xr US8889191 Sustained-release formulations of topiramate Nov 16, 2027 Supernus Pharms
Trokendi Xr US8992989 Sustained-release formulations of topiramate Nov 16, 2027 Supernus Pharms
Trokendi Xr US9549940 Sustained-release formulations of topiramate Nov 16, 2027 Supernus Pharms
Trokendi Xr US9555004 Sustained-release formulations of topiramate Nov 16, 2027 Supernus Pharms
Trokendi Xr US9622983 Sustained-release formulations of topiramate Nov 16, 2027 Supernus Pharms
Topamax US7125560

(Pediatric)

Pharmaceutical composition of topiramate Sep 01, 2019

(Expired)

Janssen Pharms
Topamax Sprinkle US7125560

(Pediatric)

Pharmaceutical composition of topiramate Sep 01, 2019

(Expired)

Janssen Pharms
Topamax US7125560 Pharmaceutical composition of topiramate Mar 01, 2019

(Expired)

Janssen Pharms
Topamax Sprinkle US7125560 Pharmaceutical composition of topiramate Mar 01, 2019

(Expired)

Janssen Pharms
Topamax US5998380

(Pediatric)

Treatment of migraine Apr 13, 2016

(Expired)

Janssen Pharms
Topamax US6503884

(Pediatric)

Migraine treatment method using topiramate and related compounds Apr 13, 2016

(Expired)

Janssen Pharms
Topamax US7018983

(Pediatric)

Treatment of migraine Apr 13, 2016

(Expired)

Janssen Pharms
Topamax US7498311

(Pediatric)

Treatment of migraine Apr 13, 2016

(Expired)

Janssen Pharms
Topamax Sprinkle US5998380

(Pediatric)

Treatment of migraine Apr 13, 2016

(Expired)

Janssen Pharms
Topamax Sprinkle US6503884

(Pediatric)

Migraine treatment method using topiramate and related compounds Apr 13, 2016

(Expired)

Janssen Pharms
Topamax Sprinkle US7018983

(Pediatric)

Treatment of migraine Apr 13, 2016

(Expired)

Janssen Pharms
Topamax Sprinkle US7498311

(Pediatric)

Treatment of migraine Apr 13, 2016

(Expired)

Janssen Pharms
Topamax US5998380 Treatment of migraine Oct 13, 2015

(Expired)

Janssen Pharms
Topamax US6503884 Migraine treatment method using topiramate and related compounds Oct 13, 2015

(Expired)

Janssen Pharms
Topamax US7018983 Treatment of migraine Oct 13, 2015

(Expired)

Janssen Pharms
Topamax US7498311 Treatment of migraine Oct 13, 2015

(Expired)

Janssen Pharms
Topamax Sprinkle US5998380 Treatment of migraine Oct 13, 2015

(Expired)

Janssen Pharms
Topamax Sprinkle US6503884 Migraine treatment method using topiramate and related compounds Oct 13, 2015

(Expired)

Janssen Pharms
Topamax Sprinkle US7018983 Treatment of migraine Oct 13, 2015

(Expired)

Janssen Pharms
Topamax Sprinkle US7498311 Treatment of migraine Oct 13, 2015

(Expired)

Janssen Pharms



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Topiramate's patents.

Given below is the list recent legal activities going on the following patents of Topiramate.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 30 Apr, 2024 US8298580(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 13 Feb, 2023 US9101545
Payment of Maintenance Fee, 4th Year, Large Entity 30 Jan, 2023 US10363224
Payment of Maintenance Fee, 4th Year, Large Entity 12 Dec, 2022 US10314790(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 18 May, 2022 US8889191(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 18 May, 2022 US8889190
Payment of Maintenance Fee, 8th Year, Large Entity 04 May, 2022 US8877248
Payment of Maintenance Fee, 8th Year, Large Entity 18 Aug, 2021 US8652527(Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 19 Oct, 2020 US9622983(Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 31 Jul, 2020 US9555004(Litigated)


Topiramate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Topiramate Generic API Manufacturers

Several generic applications have been filed for Topiramate. The first generic version for Topiramate was by Natco Pharma Ltd and was approved on Mar 27, 2009. And the latest generic version is by Rubicon Research Ltd and was approved on May 27, 2025.

Given below is the list of companies who have filed for Topiramate generic, along with the locations of their manufacturing plants worldwide.


Topiramate News

AbbVie's migraine medication achieves primary objective in direct comparison with topiramate - AOL.com

18 Jun, 2025

See More